Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant granulocyte colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Recombinant Granulocyte Colony-Stimulating Factor (rG-CSF) is a recombinant protein and cytokine that stimulates the bone marrow to produce and release neutrophils and hematopoietic stem cells into the bloodstream. It binds to and activates the G-CSF receptor (CSF3R) on hematopoietic progenitor cells, promoting their proliferation, differentiation, and mobilization. Clinically, rG-CSF is widely used to prevent and treat chemotherapy-induced neutropenia, to accelerate neutrophil recovery following bone marrow transplantation, and to mobilize peripheral blood progenitor cells for autologous or allogeneic stem cell transplantation. It is available under several generic and brand names, including filgrastim (Neupogen) and lenograstim (Granocyte).
- Brand names
- EuprotinFilraGranixGranocyteGrastofilLenobioNeupogenNeutroginZefylti
- Other names
- G-CSFfilgrastimgranulocyte colony-stimulating factorlenograstimrG-CSFrHuG-CSFrecombinant human granulocyte colony-stimulating factorrecombinant methionyl human granulocyte colony-stimulating factortbo-filgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)JAK (Janus kinase family)STAT (STAT family)
Beyond the preview
Go deeper on recombinant granulocyte colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant granulocyte colony-stimulating factor.